TOTAL17: This phase II/III trial is trying to understand how effective using a combination of cancer treatments (including chemotherapy, targeted therapy and immunotherapy) to target specific genes is when treating children with acute lymphoblastic leukaemia (ALL) and acute lymphoblastic lymphoma (LLy)Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Inclusion

• Diagnosis of B- or T-ALL or LLy by immunophenotyping:
• LLy participants must have < 25% tumor cells in bone marrow and peripheral blood by morphology and flow cytometry. If any of these show ≥25% blasts, patient will be considered to have leukemia. Patients with MPAL are eligible.
• Age 1-18 years (inclusive).
• No prior therapy, or limited prior therapy, including systemic glucocorticoids for one week or less, one dose of vincristine, emergency radiation therapy (e.g., to the mediastinum, head and neck, orbit, etc.) and one dose of intrathecal chemotherapy.
• Written, informed consent and assent following Institutional Review Board (IRB), National Cancer Institute (NCI), Food and Drug Administration (FDA), and Office of Human Research Protections (OHRP) Guidelines.